With a revenue increase of 24.04% in the third quarter 2026, year on year to cumulative value of $413 million, Mannkind's revenue per employee grew on a trailing twelve months basis to $ 698,260. The productivity of Mannkind's employees was 0.0%, above the company average. Within the Healthcare sector Employees of 140 other companies have achieved higher revenue per employee. While Mannkind's total ranking has deteriorated compared to the previous quarter from 1010 to 1362. Mannkind has 592 employees.
MannKind Corporation Expands Leadership and Records Impressive Revenue Growth Danbury, Conn. and Westlake Village, Calif. – On January 6, 2025, MannKind Corporation (Nasdaq: MNKD), a pioneer in the development of innovative inhaled therapeutic products for patients with endocrine disorders and orphan lung diseases, announced a significant addition to its executive team. Dominic Marasco, RPh, has been appointed as the new President of the Endocrine Business Unit. This strategic move is part of MannKind s efforts to strengthen its operations and position itself in the competitive healthcare sector.In conjunction with this leadership expansion, MannKind has also reported remarkable financial growth. The company achieved a revenue per employee figure of $1,322,772 over the trailing twelve months, marking a substantial increase of 36.73% year-on-year in the third quarter of 2024, leading to a cumulative revenue of $267 million. This achievement not only highlights the company s robust operational performance but also sets a new high watermark in its financial history.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
